### Open Access Full Text Article

## CORRIGENDUM

# Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQI In Ovarian Cancer [Corrigendum]

Luan W, Pang Y, Li R, et al. Onco Targets Ther. 2019;12:8063–8074.

The authors of this paper have advised that when they rechecked their data and figures, they found one mistake in Figure 1C on page 8065. Figure 1C reflects the effects of different concentrations of JQ1 on the apoptosis level.

The authors repeated the statistical analysis at least three times and as a result there were many images generated. When the author checked group HO-8910 and SKOV-3 in Figure 1C, they found that they had selected 3 wrong images. The correct Figure 1C is listed below. The authors have confirmed this will not impact on the results or conclusions of this paper.



FL1-H: AnnexinV-FITC

#### **OncoTargets and Therapy**

## **Dove**press

## Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

submit your manuscript | www.dovepress.com DovePress f y in http://doi.org/10.2147/OTT.5236659 OncoTargets and Therapy 2019:12 9793

9793

С

© 2019 Luan et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 42 and 5 of our Terms (https://www.dovepress.com/terms.php).